Thiram
CAS 137-26-8
Thiram (CAS 137-26-8) is a Phase 2 pharmaceutical compound with 13 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 14324.381065088757 nM | 138 | - |
| - | GI50 | 23576.631640625 nM | 70 | - |
| - | IC50 | 14234.699999999999 nM | 28 | - |
| - | MIC | 20800 nM | 7 | - |
| - | AC50 | 5034.183333333333 nM | 6 | - |
| - | EC50 | 13.833333333333334 ug.mL-1 | 3 | - |
| - | EC50 | 143 nM | 2 | - |
| - | Kd | 47000 nM | 2 | - |
| - | IC50 | 0.76 | 1 | - |
| Fructose-1,6-bisphosphatase 1 Enzyme |
IC50 | 5.64 | - | Homo sapiens |
| Fatty-acid amide hydrolase 1 Enzyme |
IC50 | 4.35 | - | Homo sapiens |
| Aldehyde dehydrogenase, mitochondrial Enzyme |
IC50 | 6.5 | - | Homo sapiens |
| Retinal dehydrogenase 1 Enzyme |
IC50 | 7.7 | - | Homo sapiens |
| Gamma-butyrobetaine dioxygenase Enzyme |
IC50 | 5.24 | - | Homo sapiens |
| Monoglyceride lipase Enzyme |
IC50 | 6.01 | - | Homo sapiens |
| Bifunctional protein GlmU Enzyme |
IC50 | 4.05 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Protein-lysine 6-oxidase Enzyme |
IC50 | 5.98 | - | Homo sapiens |
| Lysyl oxidase homolog 3 Enzyme |
IC50 | 6.96 | - | Homo sapiens |
| Lysyl oxidase homolog 4 Enzyme |
IC50 | 6.75 | - | Homo sapiens |
| Histone-lysine N-methyltransferase EHMT2 Enzyme |
IC50 | 6.26 | - | Homo sapiens |
| Histone-lysine N-methyltransferase EHMT1 Enzyme |
IC50 | 5.96 | - | Homo sapiens |
| Lysyl oxidase homolog 2 Enzyme |
IC50 | 6.77 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Thiram used for in pharmaceutical contexts?
Thiram (CAS 137-26-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Thiram?
No adverse-event association or SIDER side-effect rows are rendered for Thiram in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Thiram also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Thiram with EU status "prohibited".
What clinical phase is Thiram in?
Thiram is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Thiram?
Thiram has 22 bioactivity rows in this page query. Rendered target entries include Fructose-1,6-bisphosphatase 1, Fatty-acid amide hydrolase 1, Aldehyde dehydrogenase, mitochondrial, Retinal dehydrogenase 1, Gamma-butyrobetaine dioxygenase.